Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-29
2007-05-29
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S349000, C514S353000, C546S297000, C546S304000, C546S307000
Reexamination Certificate
active
10154396
ABSTRACT:
Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided.Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
REFERENCES:
patent: 3546237 (1970-12-01), Doyle et al.
patent: 3673198 (1972-06-01), Doyle et al.
patent: 5185339 (1993-02-01), Pilkington et al.
patent: 5629428 (1997-05-01), Schlosser et al.
patent: 5783522 (1998-07-01), Schaefer et al.
patent: 5849758 (1998-12-01), Kleemann et al.
patent: 6165941 (2000-12-01), Schaefer et al.
patent: 19748439 (1999-05-01), None
patent: WO 95/33750 (1995-12-01), None
patent: WO 01/60806 (2001-08-01), None
patent: WO 01/68614 (2001-09-01), None
Caplus 122:213937.
Caplus 71:38813.
Caplus 91:140754.
Caplus 85:142218.
Caplus 81:105345.
Caplus 124:274627.
Iwamoto et al, Heterocycles, vol. 43, No. 1, pp. 199-204, 1996.
McCarthy et al., “Recent Advances with the CRF1Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications,”Current Pharmaceutical Design5:289-315 (1999).
O'Neill et al., “Total Synthesis of (±)-Cytisine,”Organic Letters2:4201-4204 (2000).
Vernin et al., “14. Etude en serie triazenique. IV1)2). Synthese et reactivite d'aryl-3-(dimethyl-3,4-isoxazolyl-5)-1-triazenes et d'arylazo-4-dimethyl-3,4-isoxazolones-5,” Helvetica Chimica Acta, vol. 62, Fasc. 5:1570-1585, (1979) Nr. 164.
Abramovitch et al., “Reaction of Pyridine 1-Oxides with Benzyne, β-Hydroxyarylation of Pyridinesvia[σ2s + π2a + π4s] Rearrangements,” Communications to the Editor, Journal of the American Chemical Society, 96:16, 5265-5267 (1974).
Lyle et al., “Regioselective Nucleophilic Addition to 3,4,-Lutidine,” J. Org. Chem., vol. 41, No. 20 3250-3252 (1976).
Horvath Raymond F.
Ping Ge
Yoon Taeyoung
Zhang Lu Yan
Corless Peter F.
Davis Zinna N.
Edwards Angell Palmer & & Dodge LLP
Kim Dwight D.
Neurogen Corporation
LandOfFree
5-substituted-2-arylpyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-substituted-2-arylpyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-substituted-2-arylpyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735728